Shares of Moderna (NASDAQ: MRNA) rose more than 10% on Friday after the biotechnology company announced the commencement of its Phase 2 study for its novel coronavirus vaccine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,